Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) EBT Margin: 2013-2025

Historic EBT Margin for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -14.45%.

  • Theravance Biopharma's EBT Margin rose 4514.00% to -14.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.81%, marking a year-over-year increase of 12320.00%. This contributed to the annual value of -69.30% for FY2024, which is 1650.00% up from last year.
  • Per Theravance Biopharma's latest filing, its EBT Margin stood at -14.45% for Q3 2025, which was down 105.17% from 279.47% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's EBT Margin registered a high of 279.47% during Q2 2025, and its lowest value of -1,589.40% during Q1 2022.
  • In the last 3 years, Theravance Biopharma's EBT Margin had a median value of -59.59% in 2024 and averaged -46.23%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 496,978bps in 2021, then plummeted by 103,212bps in 2022.
  • Quarterly analysis of 5 years shows Theravance Biopharma's EBT Margin stood at -387.84% in 2021, then skyrocketed by 29,050bps to -97.34% in 2022, then skyrocketed by 6,878bps to -28.56% in 2023, then slumped by 1,911bps to -47.66% in 2024, then surged by 4,514bps to -14.45% in 2025.
  • Its EBT Margin was -14.45% in Q3 2025, compared to 279.47% in Q2 2025 and -91.88% in Q1 2025.